VEGF Antagonist Formulations for Intravitreal Administration

摘要

Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.

主权项

1. A pre-filled syringe suitable for intravitreal administration comprising a stable ophthalmic formulation of a vascular endothelial growth factor (VEGF) antagonist, wherein the stable ophthalmic formulation comprises:
(a) 1-100 mg/ml a VEGF antagonist; (b) 0.01-5% of one or more organic co-solvent; (c) 5-40 mM of buffer; and (d) optionally comprising 1.0-7.5% of a stabilizing agent.